VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
2.740
+0.040 (1.48%)
Feb 21, 2025, 4:00 PM EST - Market closed
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 2 or -16.67% compared to the previous year.
Employees
10
Change (1Y)
-2
Growth (1Y)
-16.67%
Revenue / Employee
$49,300
Profits / Employee
-$3,414,900
Market Cap
40.42M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
VYNE News
- 2 days ago - VYNE Therapeutics to Participate in March Investor Conferences - GlobeNewsWire
- 3 days ago - VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - GlobeNewsWire
- 6 weeks ago - VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 5 months ago - VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewsWire
- 9 months ago - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 - GlobeNewsWire